���构特征与受体作用机制 — Field Notes

By Editorial Desk · published 2026-07-23 · last reviewed 2026-08-01 · Faq

fatty diacid is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.

结构特征与受体作用机制

序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。

Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。

该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。

Storage, Handling, and Analytical Verification

Peptides are sensitive to temperature, light, oxygen, and repeated freeze-thaw cycles. Semaglutide in dry form is generally held at refrigerated temperatures, while reconstituted solutions require a defined short-term storage window. Vials should be kept in secondary packaging to limit photodegradation, and exposure to alkaline conditions is avoided because it accelerates chemical degradation. Adsorption to glass and some plastics can reduce the measured concentration of dilute solutions, so low-binding polypropylene containers are preferred for analytical work. Each transfer step introduces a small risk of contamination, and closed handling practices reduce that risk.

Routine characterisation of the peptide relies on reversed-phase high-performance liquid chromatography, often paired with ultraviolet detection near 214 nanometres. Related substances such as deamidated, oxidised, and truncated sequences elute at characteristic positions and are quantified by area percentage. Electrospray ionisation mass spectrometry confirms the molecular mass and can resolve some closely related variants. Peptide mapping after enzymatic digestion provides sequence-level verification and is useful when a full identity profile is required. Method parameters such as column chemistry, gradient, and mobile-phase pH influence the separation and must be reported alongside results.

Semaglutide at a glance

Mechanism and Pharmacological Class

The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.

Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.

Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.

Related pages on this site

• Tracked briefing
• Clear guide
• Material summary
• Focused workbook
• Adaptive archive
• Reliable summary
• Clear guide
• Optimized primer

Molecular Background and Drug Class

Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.

Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.

Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.

Semaglutide Structure and Receptor Mechanism

Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.

Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.

Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.

Semaglutide Background and Drug Class

Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.

GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.

Notes from published material

In 2007, videos were shared on YouTube of alleged salvia users laughing uncontrollably, apparently unable to perform simple tasks or to communicate. In an interview published in the San Francisco Chronicle in June 2007, Daniel Siebert said that the videos "make salvia look like some horrible drug that makes people nuts and dangerous ..." and that it stops people from realizing "there are sensible ways to use something like this." Waco Representative Charles Anderson (R), who is sponsoring one of several bills to ban salvia in Texas, told colleagues at a legislative hearing about a video that depicts a salvia user behind the wheel of a car. "What we really worry about, is youngsters doing this and then getting in a vehicle or getting on a motorcycle or jumping in a pool somewhere." Michigan Representative Michael Sak (D) submitted a bill which proposed Schedule I classification of Salvia divinorum and salvinorin A. He said that if people had questions about the deleterious effects of salvia, they should go on YouTube to watch the videos. A reporter questioned Sak as to whether he had ever seen a "Girls Gone Wild" video, and whether that would incite him to make alcohol illegal (Sak replied that he hadn't yet had a chance to review the material).

==== Solvent casting and particulate leaching ==== Solvent casting and particulate leaching (SCPL) allows for the preparation of structures with regular porosity, but with limited thickness. First, the polymer is dissolved into a suitable organic solvent (e.g. polylactic acid could be dissolved into dichloromethane), then the solution is cast into a mold filled with porogen particles. Such porogen can be an inorganic salt like sodium chloride, crystals of saccharose, and gelatin or paraffin spheres. The size of the porogen particles will affect the size of the scaffold pores, while the polymer to porogen ratio is directly correlated to the amount of porosity of the final structure. After the polymer solution has been cast the solvent is allowed to fully evaporate, then the composite structure in the mold is immersed in a bath of a liquid suitable for dissolving the porogen: water in the case of sodium chloride, saccharose and gelatin or an aliphatic solvent like hexane for use with paraffin. Once the porogen has been fully dissolved, a porous structure is obtained. Other than the small thickness range that can be obtained, another drawback of SCPL lies in its use of organic solvents which must be fully removed to avoid any possible damage to the cells seeded on the scaffold.

Mergny and Lacroix determined that the addition of a bulky methyl group had a destabilizing effect on the i-motif formation when they compared phosphorothioate, the natural phosphodiester, methylphosphonate, and peptide linkages and determined that only phosphodiester and phosphorothioate oligodeoxynucleotides were capable of forming stable i-motifs.

Sources: en.wikipedia.org

Background from the literature

A cannabinoid receptor modulator is a compound that bind to the cannabinoid receptors, which are receptors in the human body that regulate multiple physiological responses, including pain sensation, mood regulation, and appetite. The two main targets of cannabinoid receptors modulators are cannabinoid receptor 1 (CBR1) and cannabinoid receptor 2 (CBR2). By stimulating or inhibiting these receptors, the modulators can achieve different therapeutic effects, such as relieving pain, reducing vomiting, improving appetite and maintaining muscle tone. Dronabinol, nabiximol, cannabidiol and nabilone are cannabinoid receptor modulators marketed as drugs for various therapeutic uses. These drugs also share some common adverse effects, including dizziness, headache, alteration in mental state, and diarrhoea. Recent research studies have explored other therapeutic potentials of the modulators, such as the antitumor effect of cannabidiol. Other cannabinoid receptor modulators are also under investigations.

12 September – Bill Wilson, lawyer and judge, judge of the Court of Appeal (2007–2008) and Supreme Court (2008–2010), King's Counsel (since 1996) (born 1946). 13 September – Stan Simpson, wool scientist (WRONZ) and science administrator, director of WRONZ (1978–1992) (born 1933). 14 September – Barry Roberts, cricketer (Northern Districts) (born 1946). 16 September Judy Tinnock, tennis player, Wimbledon mixed doubles semi-finalist (1954) (born 1931). Jack Williams, cricketer (Canterbury) (born 1931). 17 September Tenick Dennison, paediatrician, conservationist and ornithologist (born 1927). Jim Easton, oldest living man in New Zealand (108 years, 279 days), oldest living Australian World War II veteran (born 1916). Dame Joan Metge, social anthropologist (University of Auckland, Victoria University of Wellington), Te Rangi Hiroa Medal (1997) (born 1930). 20 September – Tui Te Rupe, Paralympic marathon runner (1988) (born 1943). 21 September Stu Freebairn, rugby union player (Manawatu, national team) (born 1932). William E. Shepard, religious studies academic (University of Canterbury) (born 1933). 22 September Ian Farquhar, maritime historian, businessman and local politician, chair of the Otago Harbour Board (1980–1983) (born 1931). Grant Hawke, Māori leader (Ngāti Whātua Ōrākei) (born 1944). 23 September Bruce Morrison, cricketer (Wellington, national team) (born 1933). Sir Tumu Te Heuheu, Māori leader, paramount chief of Ngāti Tūwharetoa (since 1997) (born 1941). 25 September Glynn Jones, physicist (University of Canterbury) (born 1936).

Harris also expressed support for student debt relief, and said she supported raising the minimum wage. In response to the housing crisis in the United States, Harris said she would increase home construction to reduce housing costs, arguing that it negatively impacts the economy and hurts working-class families. Harris proposed directing $40 billion to construction companies to build starter homes, and promised to send $25,000 in down-payment assistance to every first time home buyer. Harris said she would urge Congress to enforce fair housing laws and pass a bill to bar property owners from using services that "coordinate" rents through the passage of the Preventing the Algorithmic Facilitation of Rental Housing Cartels Act, and also call on Congress to pass the Stop Predatory Investing Act by removing tax benefits to Wall Street firms that buy up large numbers of single-family homes. Trump proposed further individual and corporate tax cuts beyond the 2017 Tax Cuts and Jobs Act. Trump argued that keeping taxes low for the wealthy increases job creation, and that these policies coupled with a crackdown in illegal immigration and reduction in inflation would help the middle class. Trump said he would reduce regulation of business through the creation of an efficiency commission led by Musk, along with reducing environmental regulation. By October 2024, Musk was Trump's second-largest individual campaign donor.

One industrial application for helium is leak detection. Because helium diffuses through solids three times faster than air, it is used as a tracer gas to detect leaks in high-vacuum equipment (such as cryogenic tanks) and high-pressure containers. The tested object is placed in a chamber, which is then evacuated and filled with helium. The helium that escapes through the leaks is detected by a sensitive device (helium mass spectrometer), even at the leak rates as small as 10−9 mbar·L/s (10−10 Pa·m3/s). The measurement procedure is normally automatic and is called helium integral test. A simpler procedure is to fill the tested object with helium and to manually search for leaks with a hand-held device. Helium leaks through cracks should not be confused with gas permeation through a bulk material. While helium has documented permeation constants (thus a calculable permeation rate) through glasses, ceramics, and synthetic materials, inert gases such as helium will not permeate most bulk metals.

Sources: en.wikipedia.org

Further detail

The first season of Beast Games, a reality competition show created by Jimmy "MrBeast" Donaldson was first released on Amazon Prime Video on December 19, 2024 and concluded on February 13, 2025. Jeffrey Randall Allen won the season, defeating Twana Barnett. Allen won a total grand prize of $10,000,000.

Alkylpyridines: The methyl group in picolines (methylpyridines) are reactive. 2-Picoline condenses with formaldehyde to give vinylpyridine, a comonomer in specialty polymers. All picolines undergo oxyamination to the nitriles as well as oxidation to the pyridine carboxaldehydes and carboxylic acids. Selenium dioxide converts picolines to the aldehydes. The methyl group can also be selectively chlorinated by free-radical conditions. One such derivative is 2-chloromethylpyridine. The methyl group is also more acidic, allowing formation of lithiated derivatives: CH3C5H4N + C4H9Li → LiCH2C5H4N + C4H10 Aminopyridines: 2-, 3-, and 4-Aminopyridines are susceptible to diazotization, which provides access to many further derivatives, such as the halides. Tautomerizaton of the 2- and 4-aminopyridines is disfavored, unlike the corresponding pyridinols. Hydroxypyridines: A prominent reaction of 2-hydroxypyridine and 4-hydroxypyridine is their reversible tautomerization to the corresponding pyridones. Being electron rich compared to pyridine itself, the hydroxypyridines readily undergo halogenation. Whereas 3-hydroxypyrdine has phenol-like, the 2- and 4-isomers react with halogenating agents resulting in net halide displacement of OH. Halopyridines: The halides in halopyridines are more easily displaced by nucleophiles than ordinary aryl halides. For example, 2-fluoropyridine reacts many primary and secondary amines with loss of HF. Some undergo copper-catalyzed Finkelstein reactions. Bromopyridines form Grignard reagents. 2-Bromopyridine is a convenient precursor to 2-lithiopyridine.

== Recording == The recording of Dirt began in the spring of 1992. Producer Dave Jerden, who had previously worked with the band on their debut, Facelift, wanted to work with them again. He admired Layne Staley's lyrics and voice, and Jerry Cantrell's guitar riffs. The track "Would?" produced, engineered, and mixed by Rick Parashar, was recorded before the album, and first appeared on the soundtrack to the 1992 movie Singles. Dirt was recorded at Eldorado Recording Studios in Burbank, London Bridge Studio in Seattle, and One on One Studios in Los Angeles from April to July 1992. Dirt was recorded during the Los Angeles riots that erupted following the acquittal of four LAPD officers caught on camera beating unarmed black motorist Rodney King. The riots started on the first day of recording. The band was watching television when the verdict for the incident was announced. Jerry Cantrell was in a store buying some beer when a man came in and started looting the place. Cantrell also got stuck in traffic and saw people pulling each other out of their cars and beating them. The band tried to get out of Los Angeles without getting hurt while residents were protesting against police brutality. They took Slayer vocalist Tom Araya with them and went to the Joshua Tree desert for four or five days until things calmed down, then moved back into the studio and started recording the album. While recording the album, Staley, who had previously checked out of rehab, quickly went back to using heroin. Staley later went cold-turkey on his own while reading The Bad Place by Dean Koontz.

Sources: en.wikipedia.org

Frequently asked questions